
All eyes are on the U.S. Food and Drug Administration this week as the agency weighs approval of a new pill that may quickly treat and ease severe postpartum depression. Approval of the drug could help millions of women regain their emotional equilibrium following childbirth. The FDA’s decision is expected by Friday. Taken as a pill once a day for two weeks, zuranolone showed “rapid, significant and sustained” reductions in depressive symptoms when compared to a placebo, or dummy pill, according to a recent study of nearly 200 women. These improvements occurred in as few as three days and were still evident 28 and 45 days later, said study author Dr. Kristina Deligiannidis. She is a professor at the Institute of Behavioral Science at the Feinstein Institutes for Medical Research in Manhasset, N.Y. As many as 1 in 8 women in the United States develops depression immediately before or after giving birth. “Women report severe sadness or loss of interest in pleasurable activities and relationships, have significant guilt, often about not being a good enough mother or partner, low energy, poor concentration and indecisiveness, loss of appetite and irritability,” Deligiannidis said. Many also say they feel overwhelmed and are anxious, especially over the baby’s well-being, she added. Some women may start to believe that their family would be better off if they were dead, she… read on > read on >